Satsuma Pharmaceuticals Stock EBITDA
Satsuma Pharmaceuticals fundamentals help investors to digest information that contributes to Satsuma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Satsuma Stock. The fundamental analysis module provides a way to measure Satsuma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Satsuma Pharmaceuticals stock.
Satsuma |
Satsuma Pharmaceuticals Company EBITDA Analysis
Satsuma Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Satsuma Pharmaceuticals EBITDA | (58.31 M) |
Most of Satsuma Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Satsuma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Satsuma Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (58.31 Million). This is 106.65% lower than that of the Pharmaceuticals sector and 158.22% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.5% higher than that of the company.
Satsuma EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Satsuma Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics of similar companies.Satsuma Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Satsuma Fundamentals
| Return On Equity | -1.04 | |||
| Return On Asset | -0.5 | |||
| Current Valuation | (35.53 M) | |||
| Shares Outstanding | 33.15 M | |||
| Shares Owned By Insiders | 10.43 % | |||
| Shares Owned By Institutions | 57.90 % | |||
| Number Of Shares Shorted | 130.12 K | |||
| Price To Earning | 22.12 X | |||
| Price To Book | 0.42 X | |||
| EBITDA | (58.31 M) | |||
| Net Income | (70.06 M) | |||
| Cash And Equivalents | 68.06 M | |||
| Cash Per Share | 2.15 X | |||
| Total Debt | 205 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 9.18 X | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (51.52 M) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | (1.99) X | |||
| Price To Earnings To Growth | 4.50 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 25 | |||
| Beta | 0.1 | |||
| Market Capitalization | 36.8 M | |||
| Total Asset | 54.94 M | |||
| Retained Earnings | (211.79 M) | |||
| Working Capital | 46.69 M | |||
| Z Score | 99.83 | |||
| Net Asset | 54.94 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |